<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220633</url>
  </required_header>
  <id_info>
    <org_study_id>ATB-346-101</org_study_id>
    <nct_id>NCT03220633</nct_id>
  </id_info>
  <brief_title>Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Phase I Study To Assess Safety, Tolerability And Pharmacokinetics Of Single/Multiple Ascending Doses Of ATB-346 Orally Administrated In Healthy Male And Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antibe Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Algorithme Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Antibe Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, placebo-controlled, phase I study to assess safety, tolerability and&#xD;
      pharmacokinetics of single/multiple ascending doses of atb-346 orally administered in healthy&#xD;
      male and female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single ascending doses of ATB-346 given to multiple cohorts followed by multiple ascending&#xD;
      doses of ATB-346 given to multiple cohorts in order to assess its safety, tolerability, and&#xD;
      pharmacokinetics. A single dose cohort was also conducted to assess the effect of food on the&#xD;
      drug's characteristics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Within one week following single dose administration or within one week following the final dose after two weeks of treatment regimen</time_frame>
    <description>Serum chemistry and hematology laboratory measures</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>ATB-346</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of ATB-346.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATB-346</intervention_name>
    <arm_group_label>ATB-346</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Availability for the entire study period&#xD;
&#xD;
          2. Motivated volunteer and absence of intellectual problems likely to limit the validity&#xD;
             of consent to participate in the study or the compliance with protocol requirements;&#xD;
             ability to cooperate adequately; ability to understand and observe the instructions of&#xD;
             the physician or designee&#xD;
&#xD;
          3. Healthy male or female subjects aged between 18 and 55 years, inclusive, at the time&#xD;
             of informed consent&#xD;
&#xD;
          4. Body mass index (BMI) greater than or equal to 18.50 kg/m2 and below 30.00 kg/m2&#xD;
&#xD;
          5. Non- or ex-smokers. An ex-smoker is defined as someone who completely stopped smoking&#xD;
             for at least six months before Day 1 of this study&#xD;
&#xD;
          6. Clinical laboratory values within the laboratory's stated normal range; if not within&#xD;
             this range, these must be without any clinical significance&#xD;
&#xD;
          7. Have no clinically significant diseases captured in the medical history or evidence of&#xD;
             clinically significant findings on physical examination and/or clinical laboratory&#xD;
             evaluations (hematology, general biochemistry, electrocardiogram [ECG], and&#xD;
             urinalysis)&#xD;
&#xD;
          8. Willingness to adhere to the protocol requirements as evidenced by the informed&#xD;
             consent form (ICF) duly read, signed and dated by the volunteer&#xD;
&#xD;
          9. A female volunteer must meet one of the following criteria:&#xD;
&#xD;
               -  If of childbearing potential - agrees to use one of the accepted contraceptive&#xD;
                  regimens from at least 28 days prior to the first drug administration, during the&#xD;
                  study and for at least 60 days after the last dose. An acceptable method of&#xD;
                  contraception includes one of the following:&#xD;
&#xD;
                    -  Abstinence from heterosexual intercourse&#xD;
&#xD;
                    -  Systemic contraceptives (birth control pills, injectable/implant/insertable&#xD;
                       hormonal birth control products, transdermal patch)&#xD;
&#xD;
                    -  Intrauterine device (with or without hormones)&#xD;
&#xD;
                    -  Condom with spermicide&#xD;
&#xD;
               -  If of non-childbearing potential - should be surgically sterile (i.e. has&#xD;
                  undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in&#xD;
                  a menopausal state (at least one year without menses)&#xD;
&#xD;
         10. A male volunteer with sexual partners who are pregnant, possibly pregnant, or who&#xD;
             could become pregnant must meet the following criterion:&#xD;
&#xD;
               -  Participant is inapt to procreate, defined as surgically sterile (i.e. has&#xD;
                  undergone a vasectomy, it must be at least 6 months since the surgery)&#xD;
&#xD;
               -  Participant agrees to use of the accepted contraceptive regimens from first drug&#xD;
                  administration until 3 months after the last drug administration. An acceptable&#xD;
                  method of contraception includes one of the following:&#xD;
&#xD;
                    -  Abstinence from heterosexual intercourse.&#xD;
&#xD;
                    -  Condom with spermicide.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant or breastfeeding&#xD;
&#xD;
          2. Seated pulse rate less than 50 Beats per Minute (bpm) or more than 100 bpm at&#xD;
             screening&#xD;
&#xD;
          3. Seated blood pressure below 100/60 mmHg or higher than 140/90 mmHg at screening&#xD;
&#xD;
          4. History of significant hypersensitivity to naproxen, other non-steroidal&#xD;
             anti-inflammatory agents, or any related products (including excipients of the&#xD;
             formulations) as well as severe hypersensitivity reactions (like angioedema) to any&#xD;
             drugs&#xD;
&#xD;
          5. Presence of significant gastrointestinal, liver, or kidney disease, or any other&#xD;
             conditions known to interfere with the absorption, distribution, metabolism, or&#xD;
             excretion of drugs or know to potentiate or predispose to undesired effects&#xD;
&#xD;
          6. Presence of significant cardiovascular, pulmonary, hematologic, neurological,&#xD;
             psychiatric, endocrine, immunologic, or dermatologic disease&#xD;
&#xD;
          7. Suicidal tendency, history of/or disposition to seizures, state of confusion,&#xD;
             clinically relevant psychiatric diseases&#xD;
&#xD;
          8. Presence of out-of-range cardiac interval (PR &lt; 110 msec, PR &gt; 200 msec, QRS &lt; 60&#xD;
             msec, QRS &gt;110 msec and QTc &gt; 440 msec) on the screening ECG or other clinically&#xD;
             significant ECG abnormalities&#xD;
&#xD;
          9. Maintenance therapy with any drug or significant history of drug dependency or alcohol&#xD;
             abuse (&gt;3 units of alcohol per day, intake of excessive alcohol, acute or chronic)&#xD;
&#xD;
         10. Any clinically significant illness in the previous 28 days before Day 1 of this study&#xD;
&#xD;
         11. Use of any enzyme-modifying drugs, including strong inhibitors of CYP enzymes (such as&#xD;
             cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole,&#xD;
             ketoconazole, diltiazem, and HIV antivirals) and strong inducers of CYP enzymes (such&#xD;
             as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's&#xD;
             Wort) in the previous 28 days before Day 1 of this study&#xD;
&#xD;
         12. Any history of tuberculosis and/or prophylaxis for tuberculosis&#xD;
&#xD;
         13. Positive urine screening of alcohol and/or drugs of abuse&#xD;
&#xD;
         14. Positive results to HIV Ag/Ab Combo, Hepatitis B surface Antigen (HBsAg) or&#xD;
             anti-Hepatitis C Virus (HCV) tests&#xD;
&#xD;
         15. Females who are pregnant according to a positive serum pregnancy test&#xD;
&#xD;
         16. Volunteers who took an Investigational Product (in another clinical trial) in the&#xD;
             previous 28 days before Day 1 of this study or who have already participated in this&#xD;
             clinical study&#xD;
&#xD;
         17. Volunteers who donated 50 mL or more of blood in the previous 28 days before Day 1 of&#xD;
             this study&#xD;
&#xD;
         18. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical&#xD;
             studies, etc) in the previous 56 days before Day 1 of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Algorithme Pharma</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>January 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

